Categories
Change Password!
Reset Password!
Hyaluronic acid injections effectively reduce TMJ pain and improve maximum mouth opening with superior long-term benefits over platelet-rich plasma.
A new study highlights the growing clinical value of hyaluronic acid (HA) as an injectable treatment for temporomandibular joint (TMJ) disorders, demonstrating its safety and effectiveness in minimizing pain and improving jaw function.
Javier Flores-Fraile and other researchers conducted a meta-analysis comparing HA with other injectable TMJ treatments, alongside a systematic review of PubMed-indexed studies. Outcomes of interest included TMJ pain reduction, maximum mouth opening (MMO), and overall functional improvement.
HA emerged as a safe and effective injectable material for managing TMJ disorders. Clinical data showed that HA injections decrease TMJ-related pain and improve MMO, a critical indicator of jaw function. While HA illustrated consistent benefits, the analysis noted that alternative injectable materials—depending on the specific TMJ condition and individual patient needs—may be equally or even more beneficial in certain scenarios.
Ongoing research is actively exploring these alternative injectables to determine the most appropriate, condition-specific treatment strategies for TMJ disorders. When compared with platelet-rich plasma, HA illustrated superior long-term outcomes, particularly in sustained pain relief and functional improvement, positioning HA as a preferred long-term injectable therapy for TMJ dysfunction.
In patients with TMJ pain and functional impairment, HA injections show a strong safety profile and provide significant improvements in pain control and MMO. Although other injectable options remain under investigation, HA stands out for its long-term efficacy and clinical reliability, supporting its expanding role in the management of TMJ disorders.
Dental and Medical Problems
Transforming TMJ pain relief: Hyaluronic acid's efficacy in focus - a comprehensive systematic review and meta-analysis of randomized controlled trials
Javier Flores-Fraile et al.
Comments (0)